JP2012532200A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532200A5
JP2012532200A5 JP2012519672A JP2012519672A JP2012532200A5 JP 2012532200 A5 JP2012532200 A5 JP 2012532200A5 JP 2012519672 A JP2012519672 A JP 2012519672A JP 2012519672 A JP2012519672 A JP 2012519672A JP 2012532200 A5 JP2012532200 A5 JP 2012532200A5
Authority
JP
Japan
Prior art keywords
antigen
vesicle
lipid
molten
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519672A
Other languages
English (en)
Other versions
JP5854559B2 (ja
JP2012532200A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/041078 external-priority patent/WO2011005769A1/en
Publication of JP2012532200A publication Critical patent/JP2012532200A/ja
Publication of JP2012532200A5 publication Critical patent/JP2012532200A5/ja
Application granted granted Critical
Publication of JP5854559B2 publication Critical patent/JP5854559B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. 小胞形成脂質の溶融混合物を用意するステップであって、
    前記小胞形成脂質は、リン脂質、非イオン性界面活性剤、又はリン脂質及び非イオン性界面活性剤の組み合わせであってよく、非イオン性界面活性剤は1−モノパルミトイルグリセリンであってよく、
    前記小胞形成脂質は、イオン性界面活性剤、ステロイド、アジュバント、又はこれらの組み合わせをさらに含んでいてもよく、前記イオン性界面活性剤はジセチルホスフェート、ホスファチジン酸又はホスファチジルセリンであってよく、前記ステロイドはコレステロールであってよく、前記アジュバントはTLR−4アゴニストであってよい、ステップと、
    前記溶融混合物を、抗原含有小胞が形成されるように抗原を含む水溶液に添加するステップであって、
    前記水溶液は凍結保護物質をさらに含んでいてもよく、前記凍結保護物質はスクロースであってよい、ステップ
    を含み、
    前記小胞形成脂質の溶融混合物がアジュバントを含まない場合はアジュバントを添加するステップであって、前記アジュバントはTLR−3アゴニストであってよく、前記アジュバントを凍結保護物質とともに添加してもよい、ステップを含んでいてもよく、
    前記抗原含有小胞を凍結乾燥するステップを含んでいてもよく、
    凍結乾燥された後に前記抗原含有小胞を再水和するステップを含んでいてもよい、
    抗原含有小胞を調製する方法。
  2. 抗原を含む前記水溶液が、温度制御を受ける、請求項1に記載の方法。
  3. 抗原を含む前記水溶液が、前記溶融混合物を抗原を含む水溶液に添加するステップ中に50℃未満、40℃未満又は30℃未満の温度に保たれる、請求項2に記載の方法。
  4. 溶融脂質混合物が生成するように小胞形成脂質を溶融し、次に凍結乾燥された脂質生成物が生成するように前記溶融脂質混合物を凍結乾燥することにより調製された、凍結乾燥された脂質生成物を用意するステップと、
    抗原含有小胞が形成されるように、前記凍結乾燥された脂質生成物を、抗原を含む水溶液で再水和するステップと
    を含む抗原含有小胞を調製する方法。
  5. 前記溶融脂質混合物が、粘膜を横断する脂質の輸送を促進する輸送促進物質を更に含む、請求項1〜のいずれか一項に記載の方法。
  6. 前記溶融脂質混合物が、粘膜を横断する脂質の輸送を促進する輸送促進物質を含まない、請求項1〜のいずれか一項に記載の方法。
  7. 前記抗原が、ウイルスであり、前記ウイルスは弱毒化されたウイルス又は不活性化されたウイルスであってもよい、請求項1〜のいずれか一項に記載の方法。
  8. 前記抗原が、ポリペプチド、ポリヌクレオチド及び多糖からなる群から選択される、請求項1〜のいずれか一項に記載の方法。
  9. 前記抗原が、熱不安定性である、請求項のいずれか一項に記載の方法。
  10. 請求項1〜のいずれか一項に基づき調製される抗原含有小胞を含む製剤。
  11. 患者において免疫反応を引き起こすための薬剤を製造するための、請求項10に記載の製剤の使用
  12. 溶融脂質混合物が生成するように小胞形成脂質を溶融し、次に凍結乾燥された脂質生成物が生成するように前記溶融脂質混合物を凍結乾燥することにより調製された、凍結乾燥された脂質生成物を含む第1の容器と、
    第2の容器の内容物が前記第1の容器の内容物と混合されたときに、抗原含有小胞が形成されるように、抗原を含む水溶液を含む前記第2の容器と
    を備えるキット。
  13. 抗原含有小胞を含む免疫原性製剤であって、
    前記抗原含有小胞は小胞形成脂質の混合物を含み、前記小胞形成脂質は非イオン性界面活性剤及び熱不安定性抗原を含んでいてもよく、
    前記抗原含有小胞は、抗原含有小胞の形成中に前記抗原を50℃未満の温度に保つステップを含む方法によって調製される、
    免疫原性製剤。
  14. 抗原含有小胞を含む免疫原性製剤であって、
    前記抗原含有小胞は、小胞形成脂質の溶融混合物と抗原を含む水溶液を混合するステップであって、前記小胞形成脂質は非イオン性界面活性剤を含んでいてもよく、前記水溶液中に存在する抗原の少なくとも50%が小胞に取り込まれる、ステップを含む方法によって調製される、免疫原性製剤。
  15. 溶融脂質混合物が生成するように小胞形成脂質を溶融し、抗原含有小胞の製剤が形成されるように前記溶融脂質混合物を抗原を含む水溶液に添加し、凍結乾燥された抗原含有小胞製剤が生成するように前記抗原含有小胞製剤を凍結乾燥することにより調製された、凍結乾燥された抗原含有小胞製剤を含む第1の容器と、
    凍結乾燥された抗原含有小胞製剤を再水和するための水溶液を含む第2の容器と
    を備えるキット。
JP2012519672A 2009-07-06 2010-07-06 小胞を調製する方法及びこれから製造される製剤 Expired - Fee Related JP5854559B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22319609P 2009-07-06 2009-07-06
US61/223,196 2009-07-06
US25691209P 2009-10-30 2009-10-30
US61/256,912 2009-10-30
PCT/US2010/041078 WO2011005769A1 (en) 2009-07-06 2010-07-06 Methods for preparing vesicles and formulations produced therefrom

Publications (3)

Publication Number Publication Date
JP2012532200A JP2012532200A (ja) 2012-12-13
JP2012532200A5 true JP2012532200A5 (ja) 2013-08-22
JP5854559B2 JP5854559B2 (ja) 2016-02-09

Family

ID=43429505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519672A Expired - Fee Related JP5854559B2 (ja) 2009-07-06 2010-07-06 小胞を調製する方法及びこれから製造される製剤

Country Status (11)

Country Link
US (1) US9849173B2 (ja)
EP (1) EP2451950B9 (ja)
JP (1) JP5854559B2 (ja)
CN (2) CN102482666B (ja)
AU (1) AU2010270722B2 (ja)
BR (1) BR112012000826B1 (ja)
CA (1) CA2767392C (ja)
ES (1) ES2573427T3 (ja)
IL (2) IL217375A (ja)
MX (1) MX2012000372A (ja)
WO (1) WO2011005769A1 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1015938A2 (pt) 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
WO2013072768A2 (en) * 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) * 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
JP5650780B2 (ja) * 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) * 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EP3075393A4 (en) * 2013-11-29 2017-08-16 Terumo Kabushiki Kaisha Adjuvant composition, vaccine composition comprising same, and method for producing same
CN107405395A (zh) * 2015-03-17 2017-11-28 红杉科学有限公司 疫苗与佐剂的组合物以及治疗尿路感染的方法
AU2016273638B2 (en) * 2015-06-02 2019-06-06 Terumo Kabushiki Kaisha Adjuvant composition containing aluminum and vaccine composition containing the same
GB201612108D0 (en) * 2016-07-12 2016-08-24 Univ Strathclyde Preperation of non-ionic surfactant vesicles and variants
GB201814959D0 (en) * 2018-09-14 2018-10-31 Secr Defence Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses
CN116211827B (zh) * 2023-03-17 2024-04-05 浙江大学 一种特立帕肽固体脂质纳米粒及其制备方法和应用

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952097A (en) 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4024241A (en) 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4349538A (en) 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
JPS56115727A (en) * 1980-02-19 1981-09-11 Kuraray Co Ltd Carrier for immobilizing physiologically active substance
US4537769A (en) 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
US4894228A (en) 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4983387A (en) 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
AU603659B2 (en) 1987-03-13 1990-11-22 Micro Vesicular Systems, Inc. Lipid vesicles formed of surfactants and steroids
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5160669A (en) 1988-03-03 1992-11-03 Micro Vesicular Systems, Inc. Method of making oil filled paucilamellar lipid vesicles
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4911517A (en) 1988-09-09 1990-03-27 Square D Company Means for clamping fiber optical cable
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5817318A (en) 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
CN1022331C (zh) 1989-08-17 1993-10-06 浙江省医学科学院 甲型肝炎减毒活疫苗毒种及其制造方法
DE3934366A1 (de) 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
IT1238343B (it) 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
HU220136B (hu) 1990-06-29 2001-11-28 Chiron Corp. Eljárás liposzómákat tartalmazó vakcinakészítmény előállítására
US5250236A (en) 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
GB9207731D0 (en) 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
JPH08509202A (ja) 1992-07-08 1996-10-01 ディアノルム―ゲレーテ・ゲー・マイエルホファー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リポソーム、それを調製する方法及び薬調製におけるその用途
ATE205536T1 (de) 1992-09-18 2001-09-15 Smithkline Beecham Biolog Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe
US5393527A (en) 1993-01-04 1995-02-28 Becton, Dickinson And Company Stabilized microspheres and methods of preparation
ATE192331T1 (de) 1993-02-26 2000-05-15 Fountain Pharm Inc Abgabesystem für impfstoffe und lagerstabile vorstufenlösung zur nachträglichen verkapselung von aktivstoffen
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
CA2163860A1 (en) 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
CZ290331B6 (cs) 1993-11-17 2002-07-17 Laboratoires Om S. A. Glukosaminové disacharidy, způsob jejich přípravy a farmaceutický prostředek
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5962298A (en) 1994-01-11 1999-10-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Influenza vaccine
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
US20030104576A1 (en) 1994-10-07 2003-06-05 Jonathan W. Nyce Dna construct, composition, formulations & methods for making the construct & for modulating expression
GB9515868D0 (en) 1995-08-02 1995-10-04 Proteus Molecular Design Therapeutic method
GB9522351D0 (en) 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
US5700679A (en) 1996-06-07 1997-12-23 Novavax, Inc. Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity
US5919480A (en) 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
CN1150001C (zh) 1996-07-03 2004-05-19 卫材株式会社 含有脂质a类似物的注射剂及其制备方法
ZA975889B (en) 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
ES2305157T3 (es) * 1996-09-13 2008-11-01 Lipoxen Technologies Limited Liposomas.
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6290967B1 (en) 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
FR2760367B1 (fr) 1997-03-06 1999-04-30 Pasteur Merieux Serums Vacc Composition vaccinale destinee a la prevention ou au traitement des hepatites c
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
DK0996451T3 (da) 1997-05-20 2005-05-23 Galenica Pharmaceuticals Inc Triterpensaponinanaloger med adjuvans- og immunstimulatorisk aktivitet
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
ATE365206T1 (de) 1998-02-13 2007-07-15 Adan Rios Verfahren zur entwicklung von einem hiv impfstoff
US6503753B1 (en) 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
EP1078105B1 (en) 1998-05-12 2004-11-24 Genecure LLC Replication defective hiv vaccine
US7067134B1 (en) 1998-08-12 2006-06-27 University Of Western Ontario HIV vaccine
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9822714D0 (en) 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
CN1062770C (zh) 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
US6287570B1 (en) 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
GB9826069D0 (en) 1998-11-28 1999-01-20 Univ Leeds HIV vaccine
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
WO2001002607A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
AU5905400A (en) * 1999-07-14 2001-02-05 Board Of Regents, The University Of Texas System Methods and compositions for delivery and retention of active agents to lymph nodes
ATE286719T1 (de) 1999-07-15 2005-01-15 Inex Pharmaceuticals Corp Verfahren zur herstellung von in lipid verkapselten therapeutischen wirkstoffen
ATE292186T1 (de) 1999-07-28 2005-04-15 Stephen Smith Konditionell kontrollierter, attenuierter hiv-1 impfstoff
ES2293923T3 (es) 1999-09-24 2008-04-01 Glaxosmithkline Biologicals S.A. Vacuna intranasal contra el virus influenza.
ATE331530T1 (de) 2000-02-15 2006-07-15 Id Biomedical Corp Quebec Proteasom-influenzavirus-impfstoffzusammensetzu g
FR2806912B1 (fr) 2000-04-04 2004-07-23 Fond Mondiale Rech Et Preventi UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
ES2327103T3 (es) 2000-09-25 2009-10-26 Polymun Scientific Immunbiologische Forschung Gmbh Vacuna viva de influenzavirus y procedimiento de fabricacion.
WO2002051390A2 (en) * 2000-12-27 2002-07-04 Ares Trading S.A. Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ATE458496T1 (de) 2002-01-14 2010-03-15 Novartis Vaccines & Diagnostic Hiv-vakzine und anwendungsverfahren
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
US20050169979A1 (en) 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
CN100340289C (zh) * 2002-07-05 2007-10-03 利普生技术有限公司 增强核酸接种免疫应答的方法
US20040011840A1 (en) 2002-07-22 2004-01-22 Lovett Terry E. Rolling motorcycle bag
KR101251902B1 (ko) 2003-02-25 2013-04-08 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
CA2522379C (en) 2003-04-10 2012-10-23 Chiron Corporation The severe acute respiratory syndrome coronavirus
CA2523676A1 (en) 2003-05-15 2005-02-17 The Board Of Regents For Oklahoma State University Dna vaccine expressing ha1 of equine-2 influenza virus
EP1638610B1 (en) 2003-06-18 2015-03-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingoid polyalkylamine conjugates for vaccination
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20050095283A1 (en) 2003-09-16 2005-05-05 Aphios Corporation Compositions and methods for topically treating diseases
US20080160089A1 (en) 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
WO2005053727A2 (en) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
US20060024670A1 (en) * 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
ES2393492T3 (es) 2004-05-25 2012-12-21 Medimmune, Llc Variantes de hemaglutinina y neuraminidasa de influenza
CA2565500A1 (en) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
ATE406874T1 (de) * 2004-07-07 2008-09-15 Statens Seruminstitut Zusammensetzungen und verfahren zur stabilisierung von adjuvans-formulierungen auf lipid-basis unter verwendung von glykolipiden
ATE401057T1 (de) * 2004-10-08 2008-08-15 Alza Corp Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen
KR101316350B1 (ko) 2004-12-08 2013-10-15 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
EP1676569A1 (en) 2004-12-30 2006-07-05 Pevion Biotech Ltd. Lyophilization of virosomes
CA2540279C (en) 2005-03-01 2009-10-20 Variation Biotechnologies Inc. Hiv vaccine composition
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20090028903A1 (en) 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
US7348011B2 (en) 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
US20080213461A1 (en) 2005-06-17 2008-09-04 Georgia Tech Research Corporation Coated Microstructures and Methods of Manufacture Thereof
KR20080072934A (ko) 2005-11-25 2008-08-07 콜리 파마슈티칼 게엠베하 면역자극성 올리고리보뉴클레오티드
AU2007239095B2 (en) * 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
US20100226932A1 (en) 2006-02-22 2010-09-09 Novavax, Inc. Adjuvant and Vaccine Compositions
US8846078B2 (en) * 2006-03-21 2014-09-30 The Secretary Of State For Environment, Food & Rural Affairs Acting Through The Animal Health And Veterinary Laboratories Agency Brucellosis DNA vaccine
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
JP5072275B2 (ja) * 2006-07-03 2012-11-14 テルモ株式会社 閉鎖小胞の分離方法、製剤の製造方法および評価方法
US20090202620A1 (en) 2006-09-05 2009-08-13 Medivas, Llc Polymer-stabilized liposomal compositions and methods of use
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2068918T1 (sl) * 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
AU2008222523A1 (en) 2007-03-07 2008-09-12 Nventa Biopharmaceuticals Corporation Double-stranded locked nucleic acid compositions
WO2008121926A1 (en) 2007-03-30 2008-10-09 Particle Sciences, Inc. Particle formulations and uses thereof
EP2170382B1 (en) 2007-06-15 2013-07-31 Protheon Co., Ltd. Live vaccine comprising an attenuated influenza virus
EP2014279A1 (en) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
WO2009029695A1 (en) 2007-08-28 2009-03-05 Baxter International Inc. Method for producing viral vaccines
US20110105995A1 (en) 2008-01-16 2011-05-05 Zhu Ting F Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
CN101574394A (zh) 2008-05-09 2009-11-11 北京因科瑞斯医药科技有限公司 马钱子生物碱囊泡及其制备方法
WO2009155489A2 (en) 2008-06-19 2009-12-23 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US20110177163A1 (en) 2008-09-18 2011-07-21 Variation Biotechnologies, Inc. Compositions and methods for treating hepatitis a
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
WO2012006368A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов

Similar Documents

Publication Publication Date Title
JP2012532200A5 (ja)
Poirier et al. Hepatitis B surface antigen incorporated in dissolvable microneedle array patch is antigenic and thermostable
Bobbala et al. Is there an optimal formulation and delivery strategy for subunit vaccines?
Van Braeckel-Budimir et al. Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications
US20240002127A1 (en) Coronavirus vaccine
JP5908477B2 (ja) タンパク質をコードするrnaのリポソームによる送達に適した脂質
Gupta et al. Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization
JP6119030B2 (ja) インフルエンザを治療するための組成物及び方法
JP2019518739A5 (ja)
MX2012000372A (es) Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
JP2010505785A5 (ja)
JP2014506884A5 (ja)
JP2013533259A5 (ja)
RU2014133089A (ru) Способы и композиции для терапевтических агентов
CA2922959A1 (en) Orally administrable composition
Wilkhu et al. Investigating the role of cholesterol in the formation of non-ionic surfactant based bilayer vesicles: thermal analysis and molecular dynamics
US11304999B2 (en) Dried composition of saponin in a liposomal formulation with a neutral lipid, a sterol, and a cryoprotectant
Nguyen et al. Skin immunization with third-generation hepatitis B surface antigen using microneedles
JP7136777B2 (ja) 新規プロセス
Nielsen et al. ISCOMs as a vaccine delivery system
Yusuf et al. Phase behavior of dried–DDA liposomal formulation dispersed in HPMC matrix in the presence of saccharides
JP2018503629A5 (ja)
EP3016679B1 (en) Method for preparing virosomes
US10973900B2 (en) Dried composition
Samiei et al. Engraftment of plasma membrane vesicles into liposomes: A new method for designing of liposome-based vaccines